 The metaanalysis shows that a two-fold increase in the minimum concentration of everolimus increased the probability of tumor size reduction odds ratio 1.4, which was associated with a trend for reduced risk of PFS events risk ratio RR 0.9, but with an increased risk of grade 3 pulmonary toxicity RR1.93, Mucositis RR 1.49, and metabolic toxicity RR 1.3. 